Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Renstar Inc

Neither a doctor nor a teaching hospital

Research payments

$27,271,602

1,292 payments

Through program year 2025, Renstar Inc is reported as receiving $27,271,602 in research payments, across 1,292 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,498,361 36
2024 Research $3,400,892 39
2023 Research $4,978,121 44
2022 Research $3,648,073 39
2021 Research $3,928,896 218
2020 Research $4,068,834 343
2019 Research $3,748,424 573

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $21,777,485 190 payments
  2. Eisai Inc. $4,102,399 898 payments
  3. Ucb SA $355,184 5 payments
  4. Novo Nordisk AS $289,793 61 payments
  5. Allergan Inc. $249,996 40 payments
  6. Regeneron Pharmaceuticals, Inc. $223,521 33 payments
  7. Teva Pharmaceuticals USA, Inc. $86,262 27 payments
  8. UCB Biosciences Inc. $66,838 2 payments
  9. ITI, Inc. $62,564 26 payments
  10. GlaxoSmithKline, LLC. $57,559 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $4,534,060 9 payments
  2. A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,833,150 672 payments
  3. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,801,968 4 payments
  4. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $1,690,320 2 payments
  5. A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease $1,528,055 13 payments
  6. Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $1,448,895 7 payments
  7. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $1,041,912 2 payments
  8. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $991,582 6 payments
  9. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $959,542 9 payments
  10. Assessment of Safety, Tolerability, and Efficacy of Ly3372689 in Early Symptomatic Alzheimer's Disease $847,164 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record